FDA awards Genetesis Breakthrough Device Designation for CardioFlux 🏆

Published on
December 15, 2020
Business Wire

Genetesis, Inc. announced today that its flagship product, CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.